Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;8(8):555.
doi: 10.21037/atm.2020.01.87.

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Madhawa de Silva  1 , Malinda Itchins  1 , Nick Pavlakis  1
Affiliations
Editorial

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Madhawa de Silva et al. Ann Transl Med. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.01.87). NP—Advisory Boards/honoraria: Bristol-Myers Squibb, Merck-KgA, Boehringer Ingelheim, Astra Zeneca, Roche, Bayer, Novartis, Merck-Serono, Pfizer, Takeda, Ipsen; Research funding: Bayer, Pfizer; Travel support: Boehringer Ingelheim, Bristol-Myers Squibb, Roche. MI—Honoraria: MSD, Pfizer, Novartis, Astra Zeneca, Roche; Travel Support: MSD, Pfizer, Roche, Astra Zeneca; Advisory Board: Pfizer. M de Silva has no conflicts of interest to declare.

Comment in

Comment on

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. U.S. National Institute of Health, National Cancer Institute. SEER Cancer Statistics Review. 1975-2015.
    1. Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909. 10.1136/bmj.311.7010.899 - DOI - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. NEJM 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
    1. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934 - DOI - PMC - PubMed